FAQ on Nutriband Inc. CEO's Temporary Step Aside for Irish Presidential Candidacy

Why is Nutriband Inc.’s CEO stepping aside?

Gareth Sheridan, CEO of Nutriband Inc., is stepping aside temporarily to pursue candidacy in the Irish Presidential election, with nomination hearings and voting taking place in September and October.

Who will take over the CEO duties at Nutriband Inc. during this period?

Co-Founder and Chairman Serguei Melnik, a corporate strategy expert with over 20 years in capital markets, will assume CEO duties during Gareth Sheridan’s temporary absence.

What is Nutriband Inc.’s lead product under development?

Nutriband Inc.’s lead product under development is an abuse-deterrent fentanyl patch incorporating their AVERSA(TM) technology, designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

What is the significance of the AVERSA Fentanyl patch?

The AVERSA Fentanyl patch is positioned to be the first abuse-deterrent opioid patch, with potential peak U.S. sales estimated at $80 million to $200 million, and its technology is protected by patents in 46 countries.

When will Gareth Sheridan return to his CEO role at Nutriband Inc.?

Gareth Sheridan is expected to return to his CEO role at Nutriband Inc. after the three-month period dedicated to his Irish Presidential election campaign.

What are Nutriband Inc.’s plans for the AVERSA technology?

Nutriband Inc. plans to expand the availability of the AVERSA technology to major global medical markets, leveraging its patent protection in 46 countries.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.

What is the target for Nutriband Inc.’s NDA filing?

Nutriband Inc. is guiding toward its 2026 NDA filing target for its lead product, the AVERSA Fentanyl patch, under the temporary leadership of Serguei Melnik.